Haemo-autologous Antegrade Repriming (HAR) as Minimum Impact Perfusion Strategy for Cardiopulmonary Bypass (HARjbm1)
Anemia, Cognitive; Disorder, Due to General Medical Condition, Embolism, Air
About this trial
This is an interventional treatment trial for Anemia focused on measuring Retrograde autologous priming, RAP, HAR, cardiopulmonary bypass, Extracorporeal circulation, Gaseous microemboli, perfusion
Eligibility Criteria
Inclusion Criteria:
- All patients purposed to undergo elective cardiopulmonary bypass for cardiac valve surgery or other pathologies requiring to open heart chambers.
Exclusion Criteria:
- Urgency and emergency
- Heart transplantations
- Severe cognitive affection
- Active sepsis
- Previous anemia
- Early re-intervention
- Pre-Op extracorporeal membrane oxygenation (ECMO) support
- Hemodynamic unstability during HAR
- Any clinical condition that may force protocol deviation
Sites / Locations
- Hospital Clinico universitario Virgen de la Arrixaca
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
HAR group
Control Group
Treated group is exposed to an haematic antegrade autologous repriming of the MiECC CLass IV circuit, reducing the haemodilution related to CPB initiation to a fix amount of 300ml
Control group is not exposed to HAR. The extracorporeal circuit is a MiECC primed with 1000ml of Isofundin (crystalloid balanced solution) as an standard circuit